NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose...
United States United Kingdom Alexander Prezioso Marshall Woodworth Jamesp Tursi Development Rd Expenses
Source: prnewswire.com